Scholarlink

In Japan, detailed discussions on the indication for preimplantation genetic testing for monogenic disorders (PGT-M), i.e., “which couples are justified to undergo PGT-M,” have just begun. At present, PGT-M for low penetration or late-onset hereditary disease, such as hereditary breast and ovarian cancer (HBOC), is not publicly allowed domestically. Globally, although PGT-M for HBOC is already being implemented, it is not systematically recommended in the guidelines. Thus, its handling remains a controversial area not only from a medical standpoint but also from a bioethical perspective.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comments on the HBOC Guideline for PGT-M in Japan

  • 章节

  • 发表日期：

    2025年

查看全文
  • Aiko Sasaki

摘要

In Japan, detailed discussions on the indication for preimplantation genetic testing for monogenic disorders (PGT-M), i.e., “which couples are justified to undergo PGT-M,” have just begun. At present, PGT-M for low penetration or late-onset hereditary disease, such as hereditary breast and ovarian cancer (HBOC), is not publicly allowed domestically. Globally, although PGT-M for HBOC is already being implemented, it is not systematically recommended in the guidelines. Thus, its handling remains a controversial area not only from a medical standpoint but also from a bioethical perspective.